JP2019528042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528042A5 JP2019528042A5 JP2019500553A JP2019500553A JP2019528042A5 JP 2019528042 A5 JP2019528042 A5 JP 2019528042A5 JP 2019500553 A JP2019500553 A JP 2019500553A JP 2019500553 A JP2019500553 A JP 2019500553A JP 2019528042 A5 JP2019528042 A5 JP 2019528042A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bont
- polypeptide
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 108030001720 Bontoxilysin Proteins 0.000 claims 24
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 24
- 229920001184 polypeptide Polymers 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 230000035772 mutation Effects 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 9
- 101000761935 Clostridium botulinum Botulinum neurotoxin type X Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 241000193155 Clostridium botulinum Species 0.000 claims 3
- 206010044074 Torticollis Diseases 0.000 claims 3
- 206010013952 Dysphonia Diseases 0.000 claims 2
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 201000002849 spasmodic dystonia Diseases 0.000 claims 2
- 230000001148 spastic effect Effects 0.000 claims 2
- 206010002153 Anal fissure Diseases 0.000 claims 1
- 208000016583 Anus disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000000289 Esophageal Achalasia Diseases 0.000 claims 1
- 206010063006 Facial spasm Diseases 0.000 claims 1
- 208000009531 Fissure in Ano Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000004095 Hemifacial Spasm Diseases 0.000 claims 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000015592 Involuntary movements Diseases 0.000 claims 1
- 206010023644 Lacrimation increased Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030136 Oesophageal achalasia Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000016222 Pancreatic disease Diseases 0.000 claims 1
- 206010061334 Partial seizures Diseases 0.000 claims 1
- 208000036496 Pelvic floor dyssynergia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000004350 Strabismus Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 201000000621 achalasia Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000002898 anismus Diseases 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 206010005159 blepharospasm Diseases 0.000 claims 1
- 230000000744 blepharospasm Effects 0.000 claims 1
- 206010006514 bruxism Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 201000002866 cervical dystonia Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 230000004317 lacrimation Effects 0.000 claims 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000002851 oromandibular dystonia Diseases 0.000 claims 1
- 208000024691 pancreas disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 239000004293 potassium hydrogen sulphite Substances 0.000 claims 1
- 102220040233 rs79219465 Human genes 0.000 claims 1
- 208000026451 salivation Diseases 0.000 claims 1
- 210000001364 upper extremity Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022076994A JP7402916B2 (ja) | 2016-07-08 | 2022-05-09 | 新規ボツリヌスニューロトキシンおよびその誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662360239P | 2016-07-08 | 2016-07-08 | |
| US62/360,239 | 2016-07-08 | ||
| PCT/US2017/041255 WO2018009903A2 (en) | 2016-07-08 | 2017-07-07 | A novel botulinum neurotoxin and its derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076994A Division JP7402916B2 (ja) | 2016-07-08 | 2022-05-09 | 新規ボツリヌスニューロトキシンおよびその誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528042A JP2019528042A (ja) | 2019-10-10 |
| JP2019528042A5 true JP2019528042A5 (OSRAM) | 2020-08-20 |
| JP7158371B2 JP7158371B2 (ja) | 2022-10-21 |
Family
ID=59384231
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500553A Active JP7158371B2 (ja) | 2016-07-08 | 2017-07-07 | 新規ボツリヌスニューロトキシンおよびその誘導体 |
| JP2022076994A Active JP7402916B2 (ja) | 2016-07-08 | 2022-05-09 | 新規ボツリヌスニューロトキシンおよびその誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076994A Active JP7402916B2 (ja) | 2016-07-08 | 2022-05-09 | 新規ボツリヌスニューロトキシンおよびその誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11286473B2 (OSRAM) |
| EP (2) | EP3481852B1 (OSRAM) |
| JP (2) | JP7158371B2 (OSRAM) |
| KR (1) | KR102530925B1 (OSRAM) |
| CN (1) | CN109803980B (OSRAM) |
| AU (2) | AU2017292922B9 (OSRAM) |
| BR (1) | BR112019000278A2 (OSRAM) |
| CA (1) | CA3030155A1 (OSRAM) |
| DK (1) | DK3481852T5 (OSRAM) |
| EA (1) | EA201990229A1 (OSRAM) |
| ES (1) | ES2939001T3 (OSRAM) |
| FI (1) | FI3481852T3 (OSRAM) |
| HU (1) | HUE061429T2 (OSRAM) |
| IL (2) | IL263754B2 (OSRAM) |
| MX (1) | MX2019000151A (OSRAM) |
| NZ (1) | NZ749810A (OSRAM) |
| PL (1) | PL3481852T3 (OSRAM) |
| PT (1) | PT3481852T (OSRAM) |
| SG (2) | SG10201912102WA (OSRAM) |
| UA (1) | UA125965C2 (OSRAM) |
| WO (1) | WO2018009903A2 (OSRAM) |
| ZA (1) | ZA201900341B (OSRAM) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088381A2 (en) | 2010-12-22 | 2012-06-28 | President And Fellows Of Harvard College | Continuous directed evolution |
| CN120118892A (zh) * | 2012-11-21 | 2025-06-10 | 益普生生物创新有限公司 | 用于制备经蛋白水解处理的多肽的方法 |
| WO2015134121A2 (en) | 2014-01-20 | 2015-09-11 | President And Fellows Of Harvard College | Negative selection and stringency modulation in continuous evolution systems |
| US10920208B2 (en) | 2014-10-22 | 2021-02-16 | President And Fellows Of Harvard College | Evolution of proteases |
| WO2016168631A1 (en) | 2015-04-17 | 2016-10-20 | President And Fellows Of Harvard College | Vector-based mutagenesis system |
| EP3285800B1 (en) * | 2015-04-24 | 2019-09-18 | Consiglio Nazionale Delle Ricerche | A new therapeutic use of the botulinum neurotoxin serotype a |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US10392674B2 (en) | 2015-07-22 | 2019-08-27 | President And Fellows Of Harvard College | Evolution of site-specific recombinases |
| WO2017015559A2 (en) | 2015-07-23 | 2017-01-26 | President And Fellows Of Harvard College | Evolution of bt toxins |
| US10612011B2 (en) | 2015-07-30 | 2020-04-07 | President And Fellows Of Harvard College | Evolution of TALENs |
| IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and uses thereof |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EA201892643A1 (ru) * | 2016-05-16 | 2019-06-28 | Президент Энд Феллоуз Оф Гарвард Колледж | Способ очистки и активации ботулинического нейротоксина |
| SG10201912102WA (en) | 2016-07-08 | 2020-02-27 | Childrens Medical Center | A novel botulinum neurotoxin and its derivatives |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11040090B2 (en) * | 2016-12-08 | 2021-06-22 | Prime Bio, Inc | Botulinum neurotoxin compositions |
| US11447809B2 (en) | 2017-07-06 | 2022-09-20 | President And Fellows Of Harvard College | Evolution of tRNA synthetases |
| US12060553B2 (en) | 2017-08-25 | 2024-08-13 | President And Fellows Of Harvard College | Evolution of BoNT peptidases |
| WO2019056002A1 (en) | 2017-09-18 | 2019-03-21 | President And Fellows Of Harvard College | CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS |
| WO2019067815A2 (en) * | 2017-09-29 | 2019-04-04 | Children's Medical Center Corporation | NEUROTOXIN-LIKE TOXIN AND USES THEREOF |
| KR20200115584A (ko) | 2018-01-30 | 2020-10-07 | 칠드런'즈 메디컬 센터 코포레이션 | 바실루스 시스템을 이용한 보툴리눔 신경독소의 생산 |
| WO2019241649A1 (en) | 2018-06-14 | 2019-12-19 | President And Fellows Of Harvard College | Evolution of cytidine deaminases |
| EP3856923A1 (en) | 2018-09-28 | 2021-08-04 | Ipsen Biopharm Limited | Cell-based clostridal neurotoxin assays |
| GB201815844D0 (en) | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| GB201815817D0 (en) * | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| US20220220466A1 (en) * | 2019-04-17 | 2022-07-14 | Children's Medical Center Corporation | Catalytically inactive botulinum neurotoxin-like toxins and uses thereof |
| GB201907016D0 (en) | 2019-05-17 | 2019-07-03 | Ipsen Biopharm Ltd | Screening method to determine suitability for participation in a clinical trial |
| US20220259269A1 (en) * | 2019-07-15 | 2022-08-18 | President And Fellows Of Harvard College | Evolved botulinum neurotoxins and uses thereof |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| CN110938150B (zh) * | 2019-12-16 | 2021-08-31 | 中国人民解放军军事科学院军事医学研究院 | E型肉毒毒素重组l-hn抗原的制备方法及其应用 |
| WO2021125866A1 (ko) * | 2019-12-18 | 2021-06-24 | 성균관대학교산학협력단 | 보툴리눔 신경 독소의 안전한 제조 방법 |
| US20240082369A1 (en) * | 2020-12-21 | 2024-03-14 | Children's Medical Center Corporation | Improved receptor-binding domain of botulinum neurotoxin a and uses thereof |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| CN113495106B (zh) * | 2021-02-10 | 2023-08-25 | 中国人民解放军军事科学院军事医学研究院 | 样品检测方法 |
| CN114957482B (zh) * | 2021-02-26 | 2024-09-24 | 重庆誉颜制药有限公司 | 一种经修饰的神经毒素的单链多肽及其用途 |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| US20240158773A1 (en) * | 2021-03-15 | 2024-05-16 | Children's Medical Center Cprporation | Engineered botulinum neurotoxin a protease domain with improved efficacy |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| CA3213914A1 (en) | 2021-03-30 | 2022-10-06 | Mikhail KALINICHEV | Treatment of pain & inflammatory disorders |
| KR20250060320A (ko) * | 2021-03-30 | 2025-05-07 | 입센 바이오팜 리미티드 | 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소 |
| US20240216487A1 (en) * | 2021-04-26 | 2024-07-04 | Shanghaitech University | Intramuscular compositions of botulinum neurotoxins |
| CA3228426A1 (en) * | 2021-08-06 | 2023-02-09 | Kao Corporation | Nucleic acid structure utilizing snare |
| CA3234608A1 (en) | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| JP2025519507A (ja) * | 2022-06-10 | 2025-06-26 | メディトックス インク． | ボツリヌス毒素安定化組成物、それを含むボツリヌス毒素製剤及びそれに用いるためのポリペプチド |
| CN115785237B (zh) * | 2022-09-01 | 2023-06-16 | 上海蓝晶生物科技有限公司 | 一种重组肉毒杆菌毒素及其制备方法 |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| CN119968211A (zh) | 2022-09-30 | 2025-05-09 | 益普生生物制药有限公司 | 用于治疗膀胱疼痛综合症的梭菌神经毒素 |
| GB202307439D0 (en) | 2023-05-18 | 2023-07-05 | Ipsen Biopharm Ltd | Treatment of a headache disorder with botylinum neurotoxin a |
| CN116813727B (zh) * | 2023-06-08 | 2025-06-06 | 苏州德进生物制药有限公司 | 一种a型肉毒毒素的制备方法及其应用 |
| WO2025093844A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| WO2025093845A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
| CN118388606B (zh) * | 2024-04-25 | 2025-09-23 | 武汉大学 | 一种结合蛋白Bntifitin及其在制备用于治疗冠状病毒感染的药物中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0825869B2 (ja) | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| ATE292977T1 (de) | 1994-05-09 | 2005-04-15 | William J Binder | Präsynaptische neurotoxine gegen migränekopfschmerzen |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| EP2332959B1 (en) * | 2003-12-19 | 2014-11-26 | Wisconsin Alumni Research Foundation | Method and compositions for detecting botulinum neurotoxin |
| EP1850866A4 (en) * | 2005-01-27 | 2009-07-08 | Univ California | MONOCLONAL THERAPEUTIC ANTIBODIES FOR THE NEUTRALIZATION OF BOTULIN NEUROTOXINES |
| CA2601592A1 (en) * | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| AU2007347781B2 (en) * | 2006-07-11 | 2013-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
| CN100577149C (zh) * | 2006-12-21 | 2010-01-06 | 北京民海生物科技有限公司 | 一种治疗用a型肉毒毒素冻干粉针剂新型冻干保护剂配方 |
| WO2009014854A1 (en) | 2007-07-26 | 2009-01-29 | Allergan, Inc. | Methods of activiting clostridial toxins |
| KR20120107988A (ko) * | 2009-12-16 | 2012-10-04 | 알러간, 인코포레이티드 | 통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소 |
| RU2561465C2 (ru) * | 2010-05-20 | 2015-08-27 | Аллерган, Инк. | Разрушаемые клостридиальные токсины |
| WO2012041761A2 (en) * | 2010-09-28 | 2012-04-05 | Merz Pharma Gmbh & Co. Kgaa | Botulinum neurotoxin polypeptides exhibiting a prolonged activity |
| CN108178801B (zh) * | 2012-05-30 | 2022-05-03 | 哈佛大学校长及研究员协会 | 工程化的肉毒神经毒素 |
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| CN107108703B (zh) * | 2015-01-09 | 2022-09-23 | 益普生生物创新有限公司 | 阳离子神经毒素 |
| CN115925835A (zh) * | 2015-03-26 | 2023-04-07 | 哈佛大学校长及研究员协会 | 工程改造的肉毒杆菌神经毒素 |
| GB201505306D0 (en) * | 2015-03-27 | 2015-05-13 | Ipsen Biopharm Ltd | Chimeric polypeptides |
| WO2017035508A1 (en) * | 2015-08-27 | 2017-03-02 | Collier R John | Compositions and methods for treatment of pain |
| CA3026492A1 (en) * | 2016-06-08 | 2017-12-14 | Sicai ZHANG | Engineered botulinum neurotoxins |
| SG10201912102WA (en) * | 2016-07-08 | 2020-02-27 | Childrens Medical Center | A novel botulinum neurotoxin and its derivatives |
| WO2018039506A1 (en) * | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| EP3312290A1 (en) * | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| EP3529371B1 (en) * | 2016-10-21 | 2022-06-22 | Toxogen GmbH | A functional detection assay devoid of antibodies for serotyping of botulinum neurotoxins |
| US20190364907A1 (en) | 2017-07-21 | 2019-12-05 | The Regents Of The University Of California | Compositions of mosquitocidal clostridial proteins and methods of use |
| WO2019067815A2 (en) | 2017-09-29 | 2019-04-04 | Children's Medical Center Corporation | NEUROTOXIN-LIKE TOXIN AND USES THEREOF |
| KR20200115584A (ko) * | 2018-01-30 | 2020-10-07 | 칠드런'즈 메디컬 센터 코포레이션 | 바실루스 시스템을 이용한 보툴리눔 신경독소의 생산 |
| WO2019243376A1 (en) * | 2018-06-18 | 2019-12-26 | Ipsen Biopharm Limited | Intramuscular injection of botulinum toxin for the treatment of vulvodynia |
| EP3856923A1 (en) * | 2018-09-28 | 2021-08-04 | Ipsen Biopharm Limited | Cell-based clostridal neurotoxin assays |
| GB201815817D0 (en) * | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
-
2017
- 2017-07-07 SG SG10201912102WA patent/SG10201912102WA/en unknown
- 2017-07-07 JP JP2019500553A patent/JP7158371B2/ja active Active
- 2017-07-07 CA CA3030155A patent/CA3030155A1/en active Pending
- 2017-07-07 BR BR112019000278-2A patent/BR112019000278A2/pt unknown
- 2017-07-07 EP EP17742898.4A patent/EP3481852B1/en active Active
- 2017-07-07 UA UAA201900267A patent/UA125965C2/uk unknown
- 2017-07-07 MX MX2019000151A patent/MX2019000151A/es unknown
- 2017-07-07 DK DK17742898.4T patent/DK3481852T5/da active
- 2017-07-07 HU HUE17742898A patent/HUE061429T2/hu unknown
- 2017-07-07 SG SG11201811338VA patent/SG11201811338VA/en unknown
- 2017-07-07 NZ NZ749810A patent/NZ749810A/en unknown
- 2017-07-07 EA EA201990229A patent/EA201990229A1/ru unknown
- 2017-07-07 PL PL17742898.4T patent/PL3481852T3/pl unknown
- 2017-07-07 FI FIEP17742898.4T patent/FI3481852T3/fi active
- 2017-07-07 CN CN201780042152.XA patent/CN109803980B/zh active Active
- 2017-07-07 US US16/315,698 patent/US11286473B2/en active Active
- 2017-07-07 AU AU2017292922A patent/AU2017292922B9/en active Active
- 2017-07-07 KR KR1020197003414A patent/KR102530925B1/ko active Active
- 2017-07-07 IL IL263754A patent/IL263754B2/en unknown
- 2017-07-07 PT PT177428984T patent/PT3481852T/pt unknown
- 2017-07-07 IL IL298102A patent/IL298102B2/en unknown
- 2017-07-07 EP EP22211723.6A patent/EP4212545A1/en active Pending
- 2017-07-07 WO PCT/US2017/041255 patent/WO2018009903A2/en not_active Ceased
- 2017-07-07 ES ES17742898T patent/ES2939001T3/es active Active
-
2019
- 2019-01-17 ZA ZA2019/00341A patent/ZA201900341B/en unknown
-
2021
- 2021-12-20 US US17/555,570 patent/US20220177867A1/en active Pending
-
2022
- 2022-05-09 JP JP2022076994A patent/JP7402916B2/ja active Active
- 2022-05-16 AU AU2022203264A patent/AU2022203264B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528042A5 (OSRAM) | ||
| FI3481852T3 (fi) | Uusi botulinum-neurotoksiini ja sen johdannaisia | |
| JP2015519362A5 (OSRAM) | ||
| AR108689A1 (es) | Neurotoxinas clostridiales quiméricas | |
| JP2019216735A5 (OSRAM) | ||
| JP2019523015A5 (OSRAM) | ||
| JP2024012421A5 (OSRAM) | ||
| RU2017134357A (ru) | Сконструированный ботулинический нейротоксин | |
| AR132701A2 (es) | Neurotoxinas catiónicas | |
| CN103228286A (zh) | 可降解梭菌毒素 | |
| RU2015107240A (ru) | Способ производства протеолитически процессированных полипептидов | |
| US8440204B2 (en) | Subtype of Closteridium botulinum neurotoxin type A and uses thereof | |
| JP2019533430A5 (OSRAM) | ||
| JP2016513082A5 (OSRAM) | ||
| CA3051785A1 (en) | Improved use of botulinum neurotoxin in the treatment of sialorrhea | |
| TW201718627A (zh) | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 | |
| US11952601B2 (en) | Recombinant botulinum toxin with increased duration of effect | |
| US11453903B2 (en) | Production of activated clostridial neurotoxins | |
| JP2024107016A (ja) | ボツリヌス神経毒素ａサブタイプ６および薬理学的使用方法 | |
| RU2019108257A (ru) | Сконструированный ботулинический нейротоксин | |
| JPWO2019162376A5 (OSRAM) | ||
| RU2020131317A (ru) | Биогибрид ботулинического нейротоксина | |
| NZ747619B2 (en) | Chimeric neurotoxins | |
| JPWO2022189807A5 (OSRAM) | ||
| RU2023125799A (ru) | Модифицированные клостридиальные нейротоксины |